All Stories

  1. Development and Validation of Staging Systems for AA Amyloidosis

    Article • Journal of the American Society of Nephrology, March 2024, Wolters Kluwer Health

    Giovanni Palladini

  2. An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis

    Article • Expert Opinion on Pharmacotherapy, September 2019, Taylor & Francis

    Giovanni Palladini

  3. Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations

    Article • Amyloid, March 2019, Taylor & Francis

    Giovanni Palladini, Professor Martino Bolognesi

  4. The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis

    Article • Amyloid, March 2019, Taylor & Francis

    Giovanni Palladini, Professor Martino Bolognesi

  5. What does minimal residual disease mean in AL amyloidosis?

    Article • Expert Opinion on Orphan Drugs, November 2018, Taylor & Francis

    Giovanni Palladini

  6. Kidney Involvement in Light Chain Amyloidosis

    Article • Journal of Onco-Nephrology, May 2017, SAGE Publications

    Giovanni Palladini

  7. A patient with AL amyloidosis with negative free light chain results

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2016, De Gruyter

    Giovanni Palladini

  8. The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2016, De Gruyter

    Giovanni Palladini